Objective To investigate relationship of the marrow blast decline index(MBDI)in AML (not APL)at the first inductive treatment for 7-10 days and the prognosis.Methods 109 cases of AML were retrospectively analyzed(not APL),to compare theⅡmarrow blast decline index in AML(not APL)at the first inductive treatment for 7-10 days in the continue relieve group,the relapse group and the non-remission group,analyzed the correlation of the MBDI and continue relapse rate,the MBDI and relapse rate.Results The MBDI mean value is 0.8856 in continue relieve group.significantly higher than that of the relapse group (mean=0.4445)and the non-remission group(mean=0.3903)(P<0.0001).The MBDl positively correlated with continue relapse rate(P<0.01);negatively correlated with relapse rate(P<0.01).Conclusion The marrow blast decline index in AML(not APL) at the first inductive treatment for 7-10 days was significant for early assesment ofthe prognosis.

Objective To evaluate the efficacy and safety of HyperCVAD/HDMTX-L regimen as salvage treatment for patients with diffuse large B-cell lymphoma. Methods A retrospective study was made to analyze the efficacy and adverse reaction of HyperCVAD/HDMTX-L regimen as salvage treatment for 54 patients with diffuse large B-cell lymphoma. 27 cases were divided in CHOP class scheme ineffective group, 24 cases in recurrence group, HyperCVAD/MA regimen were as the control group. The efficacy in the treatment of 4 cycles, side effects of all cycles and 3-year progression free survival rates of the two regimens were compared. Results In CHOP class scheme ineffective group, efficiency rate of HyperCVAD/HDMTX-L was 59.3%(16/27), 3y PFS rate was 73.3%, efficiency rate of HyperCVAD/MA was 61.9 % (13/21), 3y PFS rate was 61.5%. There was no significant difference in efficiency and PFS rate between the two groups (P>0.05). In recurrence group, efficiency rate of HyperCVAD/HDMTX-L was 47.8 % (11/23), 3y PFS rate was 54.5 %, efficiency rate of HyperCVAD/MA was 45.5 % (10/22), 3y PFS rate was 50.0 %, there was no significant difference in efficiency and PFS rate between the two groups (P> 0.05). The incidence rates of nausea and vomiting, aleukocytosis, thrombocytopenia, hemorrhage associated with chemotherapy in HyperCVAD/HDMTX-L group were significantly lower than those in the control group (all P < 0.001). Conclusion HyperCVAD/HDMTX-L regimen maybe replace HyperCVAD/MA as the salvage treatment of diffuse large B-cell lymphoma.

Objective To explore the mediating effect of coping styles on the relationship between social support and self-management among young patients with newly-diagnosed type 2 diabetes(T2DM).Methods A total of 169 young patients with newly-diagnosed T2DM at China-Japan Friendship Hospital were investigated with the Medical Coping Mmodes Questionnaire,Social Support Rating Scale and the Summary of Diabetes Self-Care Activities.Results Among young patients with newly-diagnosed T2DM,there was a positive correlation between social support and confronce coping style(r =0.250,P＜0.01).The confronce coping style was positively correlated with self-management(r=0.367,P＜0.01).Confronce coping style could explain 15.3%variance of self-management(P＜0.01).Confronce coping style had a mediating effect on the relationship between social support and self-management.Conclusions Confronce coping style has a predictive role on self-management among young patients with newly-diagnosed T2DM,and confronce coping style has a mediating effect between social support and self-management.

ObjectiveTo establish an ischemia-reperfusion model in cynomolgus macaques and to analyse the effects of edaravone intervention. MethodsA total of fifteen adult male cynomolgus macaques were randomly divided into three groups: sham operation (Sham group, n=3), ischemia-reperfusion model (Model group, n=6) and edaravone treatment (Edaravone group, n=6). Ischemic-reperfusion model of cynomolgus macaques was established by clamping the M1 branch of the left cerebral artery for 1 h. After 2 h of reperfusion, the animals in Edaravone group were injected with 0.5 mg/kg edaravone intravenously for intervention treatment, while the animals in Sham and Model groups were injected with an equal volume of normal saline intravenously, twice a day, from the 2nd to 7th day. The behavioral video recordings, clinical observations and neurological deficit scores of cynomolgus macaques were obtained, and brain edema volume and cerebral ischemia volume were statistically analyzed. ResultsCompared with the Sham group, the animals in Model group showed typical symptoms of ischemic stroke, with a significant increase in the neurological deficit score， the volumes of edema and infarct of brain tissue (all P＜0.01). Compared with Model group, the neurological deficit score, the volumes of edema and infarct of brain tissue were significantly reduced in Edaravone group (all P＜0.05). ConclusionAn animal model of ischemia-reperfusion in cynomolgus macaques was successfully established, and edaravone was confirmed to alleviate the damage caused by ischemia-reperfusion.